 |
市场调查报告书
商品编码
1673034
急性肾损伤治疗市场按类型、疗法、分销管道和地区划分Acute Kidney Injury Treatment Market, By Type, By Treatment, By Distribution Channel, By Geography |
||||||
2025 年全球急性肾损伤治疗市场规模估计为 19.6 亿美元，预计到 2032 年将达到 34.3 亿美元，2025 年至 2032 年的复合年增长率为 8.3%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025 年市场规模 | 19.6亿美元 |
| 效能资料 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025 年至 2032 年复合年增长率 | 8.30％ | 2032 年金额预测 | 34.3亿美元 |
急性肾损伤 (AKI) 是指因肾功能突然下降而导致肾臟正常清除的废物在血液中积聚的情况。这是一种严重的疾病，需要立即就医，以防止进一步的肾臟损伤和肾衰竭。全球急性肾损伤治疗市场的成长是由糖尿病和高血压等合併症盛行率的上升所推动的，这增加了 AKI 的风险。此外，新药物和治疗方法的开发正在扩大患者的治疗选择。然而，公众和医疗保健提供者对 AKI 缺乏认识可能会阻碍市场的成长。
市场动态
全球急性肾损伤治疗市场的成长是由老年人口的增加所推动的，由于随着老龄化的肾功能下降，老年人更容易患上急性肾损伤 (AKI)。根据联合国预测，到 2050 年，65 岁及以上人口数量将达到 15 亿以上。由于生活方式的改变导致慢性肾臟病盛行率的增加也将推动市场成长。然而，肾臟替代疗法的高成本可能会限制其广泛应用。缺乏对 AKI 早期诊断的认识可能会阻碍市场的成长。用于早期检测 AKI 的生物标记的开发为市场开发商扩展该领域的业务提供了机会。即时监测液体状态可实现即时客製化护理。数位健康解决方案也有助于远端患者管理。
研究的主要特点
本报告对全球急性肾损伤治疗市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设 2024 年为基准年。
它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
全球急性肾损伤治疗市场的主要企业是根据公司亮点、产品系列、关键亮点、业绩和策略等参数进行介绍的。
研究涉及的主要企业包括 Fresenius Medical Care AG & Co.KGaA、百特 (Baxter)、Angion Biomedica Corp、AM-Pharma 和 Quark Pharmaceuticals, Inc.
本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球急性肾损伤治疗市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过全球急性肾损伤治疗市场分析中使用的各种策略矩阵来促进决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购情景
4. 2020 年至 2032 年全球急性肾损伤治疗市场（按类型划分）（十亿美元）
- 介绍
- 肾前性急性肾损伤
- 肾内源性急性肾损伤
- 肾后性急性肾损伤
5. 2020 年至 2032 年全球急性肾损伤治疗市场（按疗法划分）（十亿美元）
- 介绍
- 治疗
- 药物
6. 2020-2032 年全球急性肾损伤治疗市场按通路划分（十亿美元）
- 介绍
- 医院药房
- 零售药局
- 网路药局
7. 2020 年至 2032 年全球急性肾损伤治疗市场（按地区划分）（十亿美元）
- 介绍
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- Kringle Pharma, Inc.
- AstraZeneca
- Amgen Inc.
- Gilead Sciences
- Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
第 9 章分析师建议
- 兴衰
- 一致的机会地图
第十章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global Acute Kidney Injury Treatment Market is estimated to be valued at USD 1.96 Bn in 2025 and is expected to reach USD 3.43 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.96 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.30% | 2032 Value Projection: | USD 3.43 Bn |
Acute kidney injury (AKI) refers to an abrupt loss of kidney function, resulting in the build-up of waste products in the blood that would normally be removed by the kidneys. It is a serious condition that requires prompt medical care to prevent further kidney damage and failure. Global acute kidney injury treatment market growth is driven by rising prevalence of comorbid conditions such as diabetes and hypertension that increases the risk of AKI. Furthermore, development of novel drugs and treatment approaches has expanded therapeutic options for patients. However, lack of awareness among people and healthcare providers about AKI can hamper the market growth.
Market Dynamics:
Global acute kidney injury treatment market growth is driven by rising geriatric population who are more susceptible to AKI due to age-related decline in kidney function. According to the United Nations, the number of people aged 65 years and above is projected to reach over 1.5 billion by 2050. Growing prevalence of chronic kidney diseases due to lifestyle changes can also drive the market growth. However, high costs associated with renal replacement therapies can limit widespread adoption. Lack of awareness about early diagnosis of AKI can hamper the market growth. Development of biomarkers for early detection of AKI presents lucrative opportunities for market players to expand their offerings in this area. Real-time monitoring of fluid status offers real-time customized care. Digital health solutions can also aid remote patient management.
Key features of the study:
This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute kidney injury treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Fresenius Medical Care AG & Co. KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, and Quark Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market
Detailed Segmentation-
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- Treatment Insights (Revenue, USD Bn, 2020 - 2032)
- Therapy
- Drugs
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Angion Biomedica Corp.
- AM-Pharma
- Quark Pharmaceuticals, Inc.
- Baxter International, Inc.
- Fresenius Medical Care AG & Co. KGaA
- Braun Melsungen AG
- Asahi Kasei Medical Co., Ltd.
- LG Chem
- Kringle Pharma, Inc.
- AstraZeneca
- Amgen Inc.
- Gilead Sciences
- Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Acute Kidney Injury Treatment Market, By Type
- Global Acute Kidney Injury Treatment Market, By Treatment
- Global Acute Kidney Injury Treatment Market, By Distribution Channel
- Global Acute Kidney Injury Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Acute Kidney Injury Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prerenal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intrinsic Renal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Postrenal Acute Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Acute Kidney Injury Treatment Market, By Treatment, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Acute Kidney Injury Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Acute Kidney Injury Treatment Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Angion Biomedica Corp.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AM-Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Quark Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fresenius Medical Care AG & Co. KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Braun Melsungen AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asahi Kasei Medical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LG Chem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kringle Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
- AbbVie Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
